1887

Chapter 45 : Host Response in HIV Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Host Response in HIV Infection, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch45-1.gif /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch45-2.gif

Abstract:

HIV is widely considered as capable of infecting all humans and of leading to relentless disease progression. However, there is considerable diversity in human susceptibility to HIV and in clinical responses. Understanding the basis of interindividual diversity to infection is important for the development of diagnostic tools and vaccine development. Today, numerous studies in genetics, genomics, and early applications of systems biology have delivered knowledge on immunity against HIV on the basis of differences in disease manifestations (Table 1). Research has also led to the identification of biomarkers, in particular in the form of pharmacogenetic applications. This chapter will discuss the knowledge acquired through new technologies and describe the genetic tests that are in use in clinics or that may progress to routine use.

Citation: McLaren P, Telenti A. 2016. Host Response in HIV Infection, p 655-662. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch45
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819071.ch45
1. Horton RE, McLaren PJ, Fowke K, Kimani J, Ball TB. 2010. Cohorts for the study of HIV‐1-exposed but uninfected individuals: benefits and limitations. J Infect Dis 202(Suppl 3):S377S381[CrossRef].[PubMed]
2. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:18561862[CrossRef].[PubMed]
3. Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath MJ, Thomas KK, Baeten JM, Celum C, Wald A, de Bruyn G, Mullins JI, Nakku-Joloba E, Farquhar C, Essex M, Donnell D, Kiarie J, Haynes B, Goldstein D, Partners in Prevention HSV/HIV Transmission Study Team. 2011. Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One 6:e28632[CrossRef].[PubMed]
4. Petrovski S, Fellay J, Shianna KV, Carpenetti N, Kumwenda J, Kamanga G, Kamwendo DD, Letvin NL, McMichael AJ, Haynes BF, Cohen MS, Goldstein DB, Center for HIV/AIDS Vaccine Immunology. 2011. Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS 25:513518[CrossRef].[PubMed]
5. Lane J, , et al, NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). 2013. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet 22:19031910[CrossRef].[PubMed]
6. McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ, Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Rucart P, Sandhu MS, Shea PR, Schuitemaker H, Theodorou I, Vannberg F, Veldink J, Walker BD, Weintrob A, Winkler CA, Wolinsky S, Telenti A, Goldstein DB, de Bakker PI, Zagury JF, Fellay J. 2013. Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog 9:e1003515[CrossRef].[PubMed]
7. Martin MP, Carrington M. 2013. Immunogenetics of HIV disease. Immunol Rev 254:245264[CrossRef].[PubMed]
8. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C, Coovadia H, Walker BD, Heckerman D, Goulder PJ. 2010. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol 84:98799888[CrossRef].[PubMed]
9. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944947[CrossRef].[PubMed]
10. Pereyra F, , et al, International HIV Controllers Study. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:15511557[CrossRef].[PubMed]
11. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI, International HIV Controllers Study. 2012. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 21:43344347[CrossRef].[PubMed]
12. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M. 2013. Influence of HLA-C expression level on HIV control. Science 340:8791[CrossRef].[PubMed]
13. Bashirova AA, Thomas R, Carrington M. 2011. HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol 29:295317[CrossRef].[PubMed]
14. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB, NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). 2009. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 5:e1000791[CrossRef].[PubMed]
15. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, Madden PA, Heath AC, Martin NG, Montgomery GW, Goddard ME, Visscher PM. 2010. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 42:565569[CrossRef].[PubMed]
16. Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA,. Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL, International HIV Adaptation Collaborative. 2012. Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 86:1320213216.
17. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19:156164.[PubMed]
18. Bartha I, Carlson JM, Brumme CJ, McLaren PJ, Brumme ZL, John M, Haas DW, Martinez-Picado J, Dalmau J, López-Galíndez C, Casado C, Rauch A, Günthard HF, Bernasconi E, Vernazza P, Klimkait T, Yerly S, O'Brien SJ, Listgarten J, Pfeifer N, Lippert C, Fusi N, Kutalik Z, Allen TM, Müller V, Harrigan PR, Heckerman D, Telenti A, Fellay J. 2013. A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. eLife 2:e01123[CrossRef].[PubMed]
19. Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, Bonhoeffer S. 2014. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science 343:1243727[CrossRef].[PubMed]
20. Nakaya HI, Pulendran B. 2012. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS 7:2431[CrossRef].[PubMed]
21. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Günthard HF, Goldstein DB, Telenti A, Swiss HIV Cohort Study, Center for HIV/AIDS Vaccine Immunology. 2010. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 6:e1000781[CrossRef].[PubMed]
22. Telenti A. 2014. HIV: the mixed blessing of interferon. Nature 511:537538[CrossRef].[PubMed]
23. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N, Sidahmed A, Smith AJ, Cramer EM, Zeng M, Masopust D, Carlis JV, Ran L, Vanderford TH, Paiardini M, Isett RB, Baldwin DA, Else JG, Staprans SI, Silvestri G, Haase AT, Kelvin DJ. 2009. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 119:35563572.[PubMed]
24. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barré-Sinoussi F, Benecke A, Müller-Trutwin MC. 2009. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 119:35443555.[PubMed]
25. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, Sandler NG, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miró JM, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Günthard HF, de Bakker P, Douek DC, Silvestri G, Martinez-Picado J, Telenti A. 2011. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 121:23912400[CrossRef].[PubMed]
26. Reynoso R, Laufer N, Hackl M, Skalicky S, Monteforte R, Turk G, Carobene M, Quarleri J, Cahn P, Werner R, Stoiber H, Grillari-Voglauer R, Grillari J. 2014. MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Sci Rep 4:5915[CrossRef].[PubMed]
27. Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, Jeang KT. 2008. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 5:118[CrossRef].[PubMed]
28. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, Zhang H. 2007. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13:12411247[CrossRef].[PubMed]
29. Whisnant AW, Bogerd HP, Flores O, Ho P, Powers JG, Sharova N, Stevenson M, Chen CH, Cullen BR. 2013. In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio 4:e000193[CrossRef].[PubMed]
30. Kulkarni S, Qi Y,. O'HUigin C, Pereyra F, Ramsuran V, McLaren P, Fellay J, Nelson G, Chen H, Liao W, Bass S, Apps R, Gao X, Yuki Y, Lied A, Ganesan A, Hunt PW, Deeks SG, Wolinsky S, Walker BD, Carrington M. 2013. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci USA 110:2070520710.
31. Lefebvre G, Desfarges S, Uyttebroeck F, Muñoz M, Beerenwinkel N, Rougemont J, Telenti A, Ciuffi A. 2011. Analysis of HIV-1 expression level and sense of transcription by high-throughput sequencing of the infected cell. J Virol 85:62056211[CrossRef].[PubMed]
32. Mohammadi P, Desfarges S, Bartha I, Joos B, Zangger N, Muñoz M, Günthard HF, Beerenwinkel N, Telenti A, Ciuffi A. 2013. 24 hours in the life of HIV-1 in a T cell line. PLoS Pathog 9:e1003161[CrossRef].[PubMed]
33. Mohammadi P, di Iulio J, Muñoz M, Martinez R, Bartha I, Cavassini M, Thorball C, Fellay J, Beerenwinkel N, Ciuffi A, Telenti A. 2014. Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog 10:e1004156[CrossRef].[PubMed]
34. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Van Lint C, Verdin E, Woolfrey A, Zaia J, Barré-Sinoussi F, International AIDS Society Scientific Working Group on HIV Cure. 2012. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12:607614[CrossRef].[PubMed]
35. Ciuffi A, Telenti A. 2013. State of genomics and epigenomics research in the perspective of HIV cure. Curr Opin HIV AIDS 8:176181[CrossRef].[PubMed]
36. Peng X, Sova P, Green RR, Thomas MJ, Korth MJ, Proll S, Xu J, Cheng Y, Yi K, Chen L, Peng Z, Wang J, Palermo RE, Katze MG. 2014. Deep sequencing of HIV-infected cells: insights into nascent transcription and host-directed therapy. J Virol 88:87688782[CrossRef].[PubMed]
37. Macaulay IC, Voet T. 2014. Single cell genomics: advances and future perspectives. PLoS Genet 10:e1004126[CrossRef].[PubMed]
38. Stein DR, Burgener A, Ball TB. 2013. Proteomics as a novel HIV immune monitoring tool. Curr Opin HIV AIDS 8:140146[CrossRef].[PubMed]
39. Navare AT, Sova P, Purdy DE, Weiss JM, Wolf-Yadlin A, Korth MJ, Chang ST, Proll SC, Jahan TA, Krasnoselsky AL, Palermo RE, Katze MG. 2012. Quantitative proteomic analysis of HIV-1 infected CD4+ T cells reveals an early host response in important biological pathways: protein synthesis, cell proliferation, and T-cell activation. Virology 429:3746[CrossRef].[PubMed]
40. Shetty V, Jain P, Nickens Z, Sinnathamby G, Mehta A, Philip R. 2011. Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics. Omics 15:705–717.
41. Santos S, Obukhov Y, Nekhai S, Bukrinsky M, Iordanskiy S. 2012. Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology 9:65[CrossRef].[PubMed]
42. Wojcechowskyj JA, Didigu CA, Lee JY, Parrish NF, Sinha R, Hahn BH, Bushman FD, Jensen ST, Seeholzer SH, Doms RW. 2013. Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host Microbe 13:613623[CrossRef].[PubMed]
43. Jäger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2012. Global landscape of HIV-human protein complexes. Nature 481:365370.[PubMed]
44. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR, NISC Comparative Sequencing Program. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:5562[CrossRef].[PubMed]
45. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30:423433[CrossRef].[PubMed]
46. Ideker T, Krogan NJ. 2012. Differential network biology. Mol Syst Biol 8:565[CrossRef].[PubMed]
47. Jakobsen MR, Olagnier D, Hiscott J. 2015. Innate immune sensing of HIV-1 infection. Curr Opin HIV AIDS 10:96102[CrossRef].[PubMed][PubMed]
48. Rausell A, McLaren PJ, Telenti A. 2013. HIV and innate immunity—a genomics perspective. F1000Prime Rep 5:29[CrossRef].[PubMed]
49. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC. 2014. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511:601605[CrossRef].[PubMed]
50. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P. 2013. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10:146[CrossRef].[PubMed]
51. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA, International Antiviral Society-USA Panel. 2014. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312:410425[CrossRef].[PubMed]
52. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568579[CrossRef].[PubMed]
53. Telenti A, Zanger UM. 2008. Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 48:227256[CrossRef].[PubMed]
54. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A, Swiss HIV Cohort Study. 2009. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19:300309[CrossRef].[PubMed]
55. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A, Swiss HIV Cohort Study. 2011. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 203:246257[CrossRef].[PubMed]
56. Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A, Weber R, Ledergerber B, Telenti A, Tarr PE, Swiss HIV Cohort Study. 2009. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet 2:621628[CrossRef].[PubMed]
57. Rotger M, , et al, MAGNIFICENT Consortium, INSIGHT, Swiss HIV Cohort Study. 2013. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 57:112121[CrossRef].[PubMed]
58. Rotger M, Gsponer T, Martinez R, Taffé P, Elzi L, Vernazza P, Cavassini M, Bernasconi E, Hirschel B, Furrer H, Weber R, Ledergerber B, Egger M, Telenti A, Tarr PE, Swiss HIV Cohort Study. 2010. Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. Clin Infect Dis 51:10901098[CrossRef].[PubMed]
59. Esté JA, Telenti A. 2007. HIV entry inhibitors. Lancet 370:8188[CrossRef].[PubMed]
60. Chen AK, Sengupta P, Waki K, Van Engelenburg SB, Ochiya T, Ablan SD, Freed EO, Lippincott-Schwartz J. 2014. MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production. Proc Natl Acad Sci 111:E2676E2683[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Knowledge gained from genomic research in HIV infection

Citation: McLaren P, Telenti A. 2016. Host Response in HIV Infection, p 655-662. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch45
Generic image for table
TABLE 2

Pharmacogenetic markers of interest in clinical care of HIV-infected individuals

Citation: McLaren P, Telenti A. 2016. Host Response in HIV Infection, p 655-662. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch45

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error